Opinion|Videos|April 30, 2025
Recognition of Off Episodes in Parkinson Disease
Panelists discuss how understanding and communication of off episodes for patients with Parkinson disease varies widely in clinical settings, often hindering optimal symptom management.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Patient Understanding and Discussion of Off Episodes
- Patients often struggle to recognize, characterize, and report off episodes
- Terminology confusion: Patients may use different language to describe symptoms
- Many patients accept worsening symptoms as inevitable disease progression
- Underreporting due to time constraints during clinical visits
- Patient education gaps regarding the relationship between medication timing and symptom fluctuations
- Symptom diaries and rating scales improve identification but are inconsistently used
- Technology-based monitoring offers promise for more objective assessment
- Cultural and psychological factors influence symptom reporting and help-seeking behavior
Advertisement
Related to this article
The chairman of the Neurology Service Line at Baptist Health in Kentucky discussed PREVIEW trial findings for gefelorilimab in generalized myasthenia gravis, including efficacy, safety, and what the subcutaneous C5 inhibitor could offer patients if approved.
FDA approves once-daily oral tavapadon for Parkinson disease, a first-in-class D1/D5 partial agonist that improves motor function and ON time, with key safety warnings.
PROPEL will test imeroprubart, an investigational FcRn blocker, against placebo in adults with mild to severe generalized myasthenia gravis.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of MDS!
New data from a Cure SMA survey showed that children treated with disease-modifying therapy soon after birth walk more often and have fewer comorbidities than those treated later.
A new Bayesian network meta-analysis found nipocalimab's serious adverse event rates compared favorably with other gMG therapies, while overall adverse event rates were comparable.
An updated open-label extension analysis and new MRI data from the phase 3 EPIDYS trial, presented at the 2026 AANEM Annual Meeting, add to the evidence for givinostat's long-term effects on disease progression.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Accepts Fenebrutinib NDA Under Priority Review for Relapsing and Primary Progressive MS
2
Phase 3 PROPEL Trial to Test Imeroprubart in Generalized Myasthenia Gravis
3
2026 Rachel Horne Prize Winner Sandra Vukusic, MD, PhD, on Advancing Women's Health in MS
4
Nipocalimab’s Safety Profile Slightly Favored Over Other Myasthenia Gravis Therapies, Indirect Comparison Shows
5